Merck, C5976-5MG, CL 316,243 hydrate

Application
CL 316,243 hydrate has been used:
as a β-agonists to inject mice and study its effect on the expression of mammalian major facilitator superfamily domain-containing protein (Mfsd2a)
as an adrenergic agonist to stimulate adrenergic response in order to study the metabolic activity of brown, beige and white adipose tissues in mice
as a β3-adrenergic agonist to inject mice for in vivo lipolytic challenge

Biochem/physiol Actions
CL 316,243 is a β3 adrenoceptor agonist; anti-obesity agent.
β Adrenoceptor is expressed in a number of tissues such as heart, adipose tissue, colon and other tissues. It is associated with many different biological functions. β Adrenoceptor fills in as an objective for treating type 2 diabetes, heart failure, cachexia, obesity, metabolic disorder, issues related with bladder, colon and malignant tumor growth. Depression and anxiety can also be treated via β adrenoceptor. CL 316,243 is known to have antidiabetic action via β adrenoceptor. It is a potent stimulator of lipolysis. It also activates β3- adrenoceptors on neurons in hypothalamic areas that are important in the central regulation of appetite.
Features and Benefits
This compound is a featured product for Neuroscience research. Click here to discover more featured Neuroscience products. Learn more about bioactive small molecules for other areas of research at sigma.com/discover-bsm.
This compound is featured on the β-Adrenoceptors page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.
This compound was developed by Wyeth. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.